

News ATA GLANCE



From generics to innovation: Indian...

► Page No. 6



Scientific infrastructure, supply-chain capability...

► Page No. 22



India's pharma future hinges on balancing...

► Page No. 25



Innovation, trust and preventive healthcare ...

► Page No. 36

iPHEX 2026: Indian pharma industry eyes \$1.4 bn export opportunities

OUR BUREAU, MUMBAI

THE Pharmaceuticals Export Promotion Council of India (Pharmexil) has set an ambitious target of unlocking approximately USD 1.4 billion in export business opportunities through the upcoming 12th edition of iPHEX 2026, scheduled from September 7-9 at Bharat Mandapam, New Delhi. The three day exhibition and conference

arrives at a pivotal moment for India's pharmaceutical sector, which recorded a 6.8% growth in exports in Q1 FY27 compared to the same period last year.

This growth underscores India's resilience in a complex global trade environment, where supply chain disruptions, pricing pressures, and regulatory challenges continue to test exporters. Against this backdrop, iPHEX 2026 is being positioned not merely as

a trade fair but as a strategic platform to connect Indian manufacturers with international buyers, strengthen trust, and convert conversations into concrete business deals.

Scale and Scope of iPHEX 2026

The event promises to be one of the largest gatherings of pharmaceutical stakeholders in Asia. With 800+ exhibitors, 600 overseas companies, and

CONTINUED ON p2►

ENRICHING WORLD WITH
ENZYMES & PROBIOTICS!

**Syngenic
BIOSCIENCE**

Pellets for Food & Nutraceutical

- Menthol Pellets
- Sorbitol Pellets
- Bacillus Coagulans Pellets
- Sugar Spheres
- Bacillus Clausi Pellets
- Dried Ferrous Sulphate
- Simethicone Pellets
- Folic Acid Pellets
- Pancreatin Pellets
- Carbonyl Iron,
- Activated Charcoal Pellets
- Folic Acid Pellets Blend
- Alpha Lipoic Acid Pellets

PHARMA ENZYME

- Bromelain 600-2400 GDU
- Serratiopeptidase IP
- Trypsin Chymotrypsin Mix (6:1)
- Trypsin USP/BP
- Pancreatin USP/IP/BP/EP
- Veg Pancreatin
- Pepsin IP
- Fungal Diastase IP
- Papain IP/USP

FOOD ENZYME

- Fungal Amylase 10000 - 150000 SKB U/g
- Acid Protease 20000-600000 HUT/g
- Rennet 2000-15000 IMC U/g
- Alkaline Protease 5000-500000 u/g
- Bromelain 600-2400 CDU/g
- Neutral Protease 25000-500000 u/g
- Lactase 2000-100000 ALU/g
- Lipase 10000-200000 FIP U/g
- Papain 50-1000 TU/mg
- Maltogenic Amylase 2000-15000 MAN U/g
- Bacterial Amylase 2000 - 50000 BAU/g
- Alpha Galactosidase 1500-30000 GAL U/g
- Phospholipase 2000 - 10000 U/g
- Acid Cellulase 10000-200000 CNC U/g
- Bromelain 600-2400 GDU/g
- Neutral Cellulase 5000-50000 U/g
- Pectinase 10000-200000 U/g
- Polygalacturonase 5000-40000 PCU/g
- Xylanase 5000-200000 U/g
- Polygalacturonase 5000-40000 PGU/g
- Xylanase 5000-200000 XU/g
- Dextranase 5000-100000 U/g
- Beta Glucanase 5000-100000 BGU/g
- Transglutaminase 100-2000 U/g
- Laccase 2000-50000 U/g
- Veg Pancreatin
- Lysozyme 2000-30000 U/mg
- Glucose Isomerase 1000-10000 U/gm

PROBIOTICS FOR NUTRACEUTICAL & ANIMAL FEED

- Bacillus Clausii 10-150 BN
- Lactobacillus Brevis 10-200 BN
- Lactobacillus Paracasei 10-400 BN
- Streptococcus Thermophilus 10-100 BN
- Bacillus Coagulans 10-200 BN
- Lactobacillus Buchneri 10-200 BN
- Lactobacillus Plantarum 10-500 BN
- Streptococcus Faecium 10-100 BN
- Bacillus Subtilis 10-200 BN
- Lactobacillus Bulgaricus 10-300 BN
- Lactobacillus Pentosus 10-100 BN
- Saccharomyces Cerevisiae 5-20 BN
- Bifidobacterium Adolescentis 10-150 BN
- Lactobacillus Casei 10-300 BN
- Lactobacillus Sakei 10-100 BN
- Saccharomyces Boulardii 5-20 BN
- Bifidobacterium Animalis 10-200 BN
- Lactobacillus Crispatus 10-100 BN
- Lactobacillus Salivarius 10-300 BN
- Bifidobacterium Animalis Lactis 10-150 BN
- Lactobacillus Delbrueckii 10-150 BN
- Lactobacillus Lactis 10-300 BN
- Lactobacillus GG 10-200 BN
- Bifidobacterium Longum 20-200 BN
- Lactobacillus Fermentum 10-300 BN
- Pediococcus Acidilactici 10-200 BN
- Bifidobacterium Infantis 10-150 BN
- Lactobacillus Gasseri 10-300 BN
- Pediococcus Pentosaceus 10-150 BN
- Enterococcus Faecium 10-200 BN
- Lactobacillus Johnsonii 10-200 BN

Corporate Office - 338.5 Square Point, Jahangirpura, Surat-395005
Manufacturing Unit - Plot-C1, Moti Naroli Village, NH-8, Kim, Surat-394111 (Guj.)
+91-86900 76795 sales@syngenicbiotech.com
www.syngenicbiotech.com

HLL signs MoU with West Bengal Government for 100 AMRIT Pharmacies

OUR BUREAU, MUMBAI

As part of its ongoing efforts to expand access to affordable healthcare, HLL Lifecare Limited (HLL), a Miniratna Central Public Sector Enterprise under the Ministry of Health & Family Welfare, Government of India, has signed a Memorandum of Understanding (MoU) with the Government of West Bengal to establish 100 AMRIT Pharmacies across the State. Affordable Medicines and Reliable Implants for Treatment (AMRIT) is a flagship initiative of the Ministry of Health & Family Welfare, Government of India, implemented by HLL since 2015.

The MoU was exchanged at Netaji Indoor Stadium, Kolkata, in the presence of Hon'ble Chief Minister Shri Suwendu Adhikari, Union Minister Smt. Anupriya Patel and other dignitaries. Representing



HLL, Shri Benny Joseph, Director (T&O), exchanged the MoU with Shri Narayan Nigam, IAS, Principal Secretary, Health, Government of West Bengal.

In West Bengal, six AMRIT Pharmacies are currently operational, including outlets at AIIMS Kalyani, Chittaranjan Na-

tional Cancer Institute, Central Railway Hospital, Kolkata and Haldia Port Hospital. The proposed 100 pharmacies will be established in government-run healthcare facilities under the Department of Health & Family Welfare, Government of West Bengal.

Launched with the objective of making quality medicines and healthcare products available at affordable prices, AMRIT has grown into a nationwide network serving patients through government and other public healthcare institutions. The first AMRIT Pharmacy was opened at AIIMS, New Delhi, on 15 November 2015.

As of 15 August 2026, AMRIT has 280 outlets across 24 States and 4 Union Territories, offering more than 6,500 medicines and healthcare products, including medicines for oncology, cardiology and diabetes, besides implants, stents, orthopaedic implants, surgical disposables and other medical consumables.

Established in 1966, HLL Lifecare Limited is a healthcare major with operations spanning contraceptives, pharmaceuticals, medical devices, diagnostics and retail pharmacy.

Dr Sanjay Agrawal develops breakthrough tinnitus treatment targeting brain pathways

OUR BUREAU, MUMBAI

SCIENTIFIC researcher Dr Sanjay Agrawal, who holds 42 patents for unique drug formulations, has developed a novel treatment aimed at alleviating tinnitus—a condition that affects nearly 15% of the global population.

The Ahmedabad-based leading pharmaceutical consultant and inventor stated that the new formulation is designed to address the neuroplastic changes and emotional amplification mechanisms that underlie tinnitus. By targeting both peripheral damage and central compensation, it holds promise for reducing the phantom sound perception and associated distress.

Tinnitus is the perception of sound—such as ringing, buzzing, or clicking—in the absence of an external auditory stimulus. It can affect one or both ears and may be intermittent or constant. Chronic tinnitus, lasting more than six months, impacts 1–2% of individuals with significant emotional and functional distress. The condition is typically categorized into subjective tinnitus (heard only by the patient) and the rarer objective tinnitus (audible to an examiner).

Key risk factors include age-related and noise-induced hearing loss, ototoxic medications (e.g., aminoglycosides, NSAIDs, chemotherapy agents), ear infections, TMJ disorders, cardiovascular diseases, psychological conditions such as anxiety, depression, and stress.

Tinnitus often stems from cochlear damage and loss of sensory hair cells, leading to reduced auditory input. The brain compensates through neuroplastic changes, increasing spontaneous activity in the auditory cortex. Emotional and attentional centres like the limbic system and prefrontal cortex further amplify the distress.

Current pharmacological treatments focus on managing associated symptoms rather than eliminating tinnitus itself. Antidepressants like amitriptyline and nortriptyline, SSRIs, benzodiazepines (clonazepam, alprazolam), anticonvulsants (gabapentin, carbamazepine), melatonin, and zinc supplementation have all been explored, though most are used off-label and show variable efficacy.

Non-drug interventions are increasingly favored. Cognitive Behavioral Therapy (CBT), Tinnitus

Retraining Therapy (TRT), sound therapy, hearing aids, mindfulness, relaxation techniques, and repetitive transcranial magnetic stimulation (rTMS) are among the most effective strategies for reducing perception and improving quality of life.

International health bodies advocate a multidisciplinary, patient-centred approach. CBT, sound therapy, and education are recommended as first-line treatments, while routine pharmacological intervention is discouraged. Guidelines from the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS), the UK's NICE, and European associations emphasize early diagnosis and psychological support. The World Health Organization (WHO) also underscores prevention through noise control and cautious use of ototoxic drugs.

Dr Agrawal's formulation aligns with global efforts to move beyond symptomatic relief toward targeted neurological intervention. By addressing both the auditory and emotional pathways involved in tinnitus, the innovation could mark a significant advancement in treatment options for millions affected worldwide.

PRIP Scheme opens up new opportunities for startups, MSMEs and industry in Pharma and MedTech sectors

OUR BUREAU, MUMBAI

THE Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers, government of India, has announced the second date for inviting applications under the Research and Innovation Promotion in Pharma and MedTech (PRIP) Scheme.

With a financial outlay of Rs 5,000 crore, the scheme aims to strengthen the country's pharma and MedTech R&D ecosystem by supporting startups, MSMEs, and large companies to move faster in the innovation value chain.

Applications are invited for two categories:

Preparatory Phase: Projects of startups and MSMEs with the objective of scaling up products or technologies at TRL (Technology Readiness Level) 1, 2 or 3 in priority areas to a higher TRL not exceeding TRL 5 will be eligible. A two-stage process will be followed for these projects, starting with a brief concept note. This will be followed by a detailed application for the selected applicants. The concept notes can be submitted by eligible MSMEs and startups directly or by ecosystem enablers on behalf of promising projects that exist in their network. Financial assistance up to Rs 5 crore per project will be provided under this scheme.